Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 10/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | EP300 | Q09472 | 2/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4466329 | 0.96 | TNF (0.60) | TNFMCL1CNR1KDM4EMEN1 | |
| SCHEMBL4473320 | 0.91 | TNF (0.53) | TNFMCL1KDM4EMEN1ALDH1A1 | |
| SCHEMBL3689068 | 0.83 | F2 (0.45) | TNFKDM4EMEN1ALDH1A1GAA | |
| SCHEMBL30396580 | 0.83 | F2 (0.45) | TNFKDM4EMEN1ALDH1A1GAA | |
| SCHEMBL1664268 | 0.82 | TNF (0.56) | TNFMCL1CNR1EP300 | |
| SCHEMBL4335712 | 0.82 | TNF (0.51) | TNFMCL1CNR1EP300 | |
| SCHEMBL860936 | 0.81 | MCL1 (0.54) | TNFMCL1MEN1KMT2A | |
| SCHEMBL8792687 | 0.79 | TNF (0.70) | TNFCNR1 | |
| SCHEMBL3919143 | 0.78 | MEN1 (0.54) | PLGPLAUKDM4EMEN1ALDH1A1 | |
| SCHEMBL27639166 | 0.78 | MTNR1A (0.46) | MCL1KDM4EGAAMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528160-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528160-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528160-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
| US-20060166983-A1 | Indole derivatives as ppar modulators | ELI LILLY AND COMPANY | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166983-A1 | Indole derivatives as ppar modulators | PPARA, PPARD, PPARG | TNF 1857/4885MCL1 3756/4885CNR1 97/4885 |
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | PPARG, PPARA, PPARD | TNF 1555/4885MCL1 3544/4885CNR1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.